United Therapeutics UTHR
NASDAQ UTHR
$506.95 +8.98 (+1.80%)
As of: Sep 9, 2026 · 3:59 PM EDT

United Therapeutics (UTHR) Capital Leases (2009)

United Therapeutics' (UTHR) quarterly Capital Leases came in at $30.3 million in Q4 2009.

Analysis

United Therapeutics (UTHR) Capital Leases (2009) Analysis & Trends

United Therapeutics has disclosed Capital Leases across 1 years of filings, most recently posting $30.3 million for Q4 2009.

  • In Q4 2009, Capital Leases changed N/A year-over-year to $30.3 million; the TTM figure through Dec 2009 stood at $30.3 million (changed N/A YoY), while the FY2009 annual figure was $30.3 million, changed N/A from the prior year.
  • Capital Leases came in at $30.3 million for Q4 2009 at United Therapeutics.
  • In the past five years, Capital Leases ranged from a high of $30.3 million in Q4 2009 to a low of $30.3 million in Q4 2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 643.26 Bn 622.50 Bn 17.26 Bn
2 AbbVie 443.31 Bn 436.74 Bn 12.70 Bn
3 Merck 364.74 Bn 357.60 Bn 12.21 Bn
4 Novartis Ag 266.46 Bn 258.77 Bn 11.24 Bn
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn
6 Sanofi 52.33 Bn 44.95 Bn 10.79 Bn
7 Revolution Medicines 43.79 Bn 43.79 Bn -
8 Incyte 25.23 Bn 20.69 Bn 1.57 Bn
9 United Therapeutics 21.67 Bn 19.01 Bn 683.80 Mn
10 Neurocrine Biosciences 15.65 Bn 15.26 Bn 935.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2009 30.33 Mn